Cancer Research Prevention Award Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 995-998, March 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Csokay, B.
Right arrow Articles by Olah, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Csokay, B.
Right arrow Articles by Olah, E.
[Cancer Research 59, 995-998, March 1, 1999]
© 1999 American Association for Cancer Research

Advances in Brief

High Frequency of Germ-Line BRCA2 Mutations among Hungarian Male Breast Cancer Patients without Family History1

Bela Csokay, Nora Udvarhelyi, Zoltan Sulyok, Istvan Besznyak, Susan Ramus, Bruce Ponder and Edith Olah2

Department of Molecular Biology, National Institute of Oncology, H-1525 Budapest, Hungary [B. C., N. U., Z. S., I. B, E. O.], and Strangeways Research Laboratories, Cambridge CB1 8RN, United Kingdom [S. R., B. P.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
To determine the contribution of BRCA1 and BRCA2 mutations to the pathogenesis of male breast cancer in Hungary, the country with the highest male breast cancer mortality rates in continental Europe, a series of 18 male breast cancer patients and three patients with gynecomastia was analyzed for germ-line mutations in both BRCA1 and BRCA2. Although no germ-line BRCA1 mutation was observed, 6 of the 18 male breast cancer cases (33%) carried truncating mutations in the BRCA2 gene. Unexpectedly, none of them reported a family history for breast/ovarian cancer. Four of six truncating mutations were novel, and two mutations were recurrent. Four patients (22%) had a family history of breast/ovarian cancer in at least one first- or second-degree relative; however, no BRCA2 mutation was identified among them. No mutation was identified in either of the genes in the gynecomastias. These results provide evidence for a strong genetic component of male breast cancer in Hungary.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
Male breast cancer is a rare disease, comprising <1% of all malignancies in men in the western world; however, in some developing areas, it is more frequent, accounting for 6–15% of all breast cancers.3 In continental Europe, the Hungarians have the highest male breast cancer mortality rates (1) . The biggest risk factor for breast cancer in both genders seems to be inherited predisposition. Approximately 5–10% of female breast cancer cases are due to inheritance of autosomal dominant susceptibility genes (2) . In the vast majority of inherited cases, the recently isolated genes BRCA1 and BRCA2 are thought to be responsible for the disease (3) . BRCA1 is estimated to account for most female breast/ovarian cancer families, but it can be infrequently detected in families with male breast cancer cases. However, breast cancer-prone families in whom male breast cancer occurred have been shown to be linked to or have mutation in BRCA2 (4) . Our earlier results did not reveal BRCA2 carrier male breast cancer patients in Hungarian breast cancer families, but two individuals without family history were found to carry BRCA2 mutations (5) .

Very little is yet known about the genetic background of male breast cancer. Somatic mutations of the p53 gene were identified in 41% of male breast cancer patients studied (6) . Defects in only a few genes have been associated with predisposition to the development of this disease. Genetic abnormalities of the androgen receptor have been reported in association with male breast cancer cases (7) . There are some reports of BRCA1 mutation involvement in male breast cancer (8, 9, 10) , but in all cases the patients with male breast cancer were members of families carrying BRCA1 mutation. There is much more evidence that inherited BRCA2 mutations increase the risk for developing male breast cancer. Several families that also contained male breast cancer patients were reported to carry BRCA2 mutations (4 , 11, 12, 13) . Men who carry a germ-line BRCA2 mutation have an increased risk of breast cancer (14) .

Although men with breast cancer also often have gynecomastia, it is still unknown whether gynecomastia per se predisposes the male breast to malignant disease. Some authors report that as many as 20–36% of the male breast cancer patients in their studies have a history of gynecomastia (15 , 16) .

In the present study, we have determined the contribution of germ-line mutations in the BRCA1 and BRCA2 genes to the pathogenesis of male breast cancer in Hungary by screening a series of 18 unselected male breast cancer patients and three patients with gynecomastia.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Patients.
Blood samples were collected from all consenting patients with male breast cancer or gynecomastia at the National Institute of Oncology (Budapest, Hungary) in the period of 1996–1998. The histopathological typing of the cases was completed by board-certified pathologists. This panel represents consecutive cases who were not selected for family history of breast/ovarian cancer; however, information on family history was available for all patients. The patients with gynecomastia did not have a medical history of Klinefelter syndrome.

BRCA1 and BRCA2 Mutation Screening.
Genomic DNA was extracted by standard methods from peripheral lymphocytes from all patients. PCR amplification of 160–550-bp DNA fragments covering the entire BRCA2 coding region and splice junctions was carried out by using a set of 44 primer pairs (5 , 11) . Similarly, all BRCA1 exons with the exception of exon 11 were amplified with a set of 23 primer pairs; exon 11 was screened in three overlapping protein truncation test fragments as reported previously (5) . Mutational screening was performed in germ-line DNA by combined multiple heteroduplex analysis and/or by single strand conformation analysis. Mutation screening in both genes was performed irrespective of identification of a mutation in one gene, because it is possible that mutations of both BRCA1 and BRCA2 may be segregating in a family, as we reported in a Hungarian breast/ovarian cancer patient (17) . PCR products from variant conformers were purified using Wizard PCR Prep DNA Purification System (Promega Corp.) and sequenced using the Thermosequenase Cyclo Sequencing kit (USB-Amersham).


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
The entire coding regions and intronic splice sites of both BRCA1 and BRCA2 were screened using multiple heteroduplex analysis/single-strand conformation analysis and protein truncation test, followed by direct sequencing of abnormalities. Six of the 18 male breast cancer cases (33%) were observed to carry truncating mutations in the BRCA2 gene (Table 1)Citation . Four of the six truncating mutations were novel; the other two alterations (277delAC and 9326insA) were reported earlier (5 , 18 , 19) . A review was conducted of the clinical and family history of the mutation carriers. None of them reported a family history for breast/ovarian cancer. Two patients (11%) had a family history of breast/ovarian cancer in at least one first-degree relative and another two (11%) in at least one second-degree relative in this unselected study; however, no BRCA2 mutation was observed among them.


View this table:
[in this window]
[in a new window]

  		Table 1 Germ-line BRCA2 mutations in Hungarian male breast cancer patients

 
No germ-line BRCA1 mutations were detected in the male breast cancer cases, nor was a mutation identified in either BRCA1 or BRCA2 in the three cases of gynecomastia; however, one patient (G2) from this group carried an unclassified BRCA2 variant allele with unclear significance (Table 2)Citation . There was no difference between mutation carriers and noncarriers with respect to clinicopathological features nor age at diagnosis (Table 3)Citation . The average age at diagnosis was 62 years; there was only an insignificant difference between the mean age of onset of carriers (58 years) and noncarriers (64 years).


View this table:
[in this window]
[in a new window]

  		Table 2 BRCA2 polymorphisms and unclassified variants

 

View this table:
[in this window]
[in a new window]

  		Table 3 Clinicopathological characteristics of patients tested in this study

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
In the first studies of BRCA2 analysis (4 , 11) , the subjects of scrutiny were mostly large families that sometimes also contained members with male breast cancer. In more recent reports (20, 21, 22) , sets of population-based male breast cancer cases were studied for the frequency of germ-line BRCA2 carriers. Here we analyzed male breast cancer patients from a hospital-based study to determine the contribution of BRCA1 and BRCA2 mutations to the pathogenesis of male breast cancer in Hungary. Frequencies reported of BRCA2 mutations in male breast cancer vary between 4% (21) and 40% (23) , the latter results are possibly influenced by a strong founder effect in that particular population. In contrast to reports by Friedman et al. (21) and Mavraki et al. (20) , who found 4 and 7% of patients carrying germ-line BRCA2 mutations, respectively, in the present study a large proportion of cases was found to carry BRCA2 mutations (6 of 18; 33%). These results are even higher than the recent reports of Haraldsson et al. (22) , who identified 21% of all cases to be BRCA2 mutation carriers.

Although in some large BRCA1 families male breast cancer patients have been shown to have germ-line BRCA1 mutations (8, 9, 10) , in the present study, as in the study of Friedman et al. (21) , no BRCA1 mutations were found. This indicates that BRCA1 germ-line mutations do not contribute substantially to male breast cancer.

In the present study, six BRCA2 mutations were identified among the male breast cancer patients. The mutations were all frameshifts predicted to result in truncated proteins. This is in agreement with previous findings, that >85% of BRCA mutations identified cause protein truncation (21) . Four of six truncating mutations were novel; the other two alterations have been reported earlier. The 277delAC mutation was reported from the United States in a large family that also contained three cases of male breast cancer (18) . The other recurrent mutation (9326insA) was first identified in Hungary (5) and has also been observed in a Hungarian male breast cancer patient living in Sweden (22) and in a French breast-ovarian cancer family that did not contain male breast cancer (19) . Several additional Hungarian breast cancer families were identified to carry 9326insA, all without male breast cancer cases.4 In a recent international collaborative study, we identified a common founding haplotype for this mutation (26) , and we have indication for a common origin of 9326insA from the Central-Eastern European region.5

The mutations we found in this study are located in exons 2, 7, 11, 16, and 23 (Table 1Citation and Fig. 1Citation ). This is not notably different from the distribution of either BRCA2 mutation spectra in male breast cancers from other studies (Fig. 1)Citation or of all BRCA2 mutations.6 Thus, there is no evidence to date that mutations in specific domains of BRCA2 may be associated with male breast cancer.



View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. BRCA2 mutation spectrum in male breast cancer patients. {blacktriangleup}, mutations found in this study (exons 2, 11, 16, and 23). {triangleup}, mutations found by Wooster et al. (4) ; Couch et al. (11) ; Phelan et al. (12) ; Tavtigian et al. (18) ; Thorlacius et al. (23) ; Friedman et al. (21) ; Mavraki et al. (20) ; Serova et al. (19) ; and Haraldsson et al. (22) . Only names of recurrent mutations are indicated.

 
The 18 breast cancer patients screened for germ-line BRCA mutations were selected without any regard for family history. However, information on family history was available for all patients (Table 3)Citation . In the present study, the proportion of patients with family history of breast/ovarian cancer in at least one first-degree relative was 11% (2 of 18), and in at least one second-degree relative, also 11% (2/18). This is in agreement with the studies of Rosenblatt et al. (24) and Friedman et al. (21) , who found similar proportions in their studies (18–10% and 17–13%, respectively). Surprisingly, no BRCA2 mutation was identified among the cases with family history; neither did the mutation carriers report family histories of breast/ovarian cancer. This is in contrast with the results of Couch et al. (11) , who identified germ-line BRCA2 mutations in 7 of 50 (14%) male breast cancer cases, 6 of 7 (85%) of whom had a family history of breast cancer. Friedman et al. (21) found two mutation carriers in their panel, one of whom had a family history. Similarly to our results, Haraldsson et al. (22) reported recently that only one of seven BRCA2 mutation carriers had a positive family history of breast cancer.

No evidence for differences in clinicopathological features was seen between mutation carriers and noncarriers. Most patients had invasive ductal carcinoma (17 of 18; 95%), including all germ-line BRCA2 mutation carriers (Table 3)Citation . This is consistent with literature data that invasive ductal carcinomas account for 84–93% of cases (25) . The average age of men at diagnosis of breast cancer is close to 65, about 5 years older than the average age for women.3 In our studies, the average age at diagnosis in carriers was not significantly lower than that of noncarriers. Compared with other BRCA2 mutations, 9326insA appears to be linked with younger age of onset in female breast cancer (26) and possibly also in male breast cancer (22) .

No mutation was identified in either of the genes in the three cases of gynecomastia; however, one patient (G2) from this group carried a missense BRCA2 variant allele (7081A->G) with unclear significance. This alteration was reported eight times in the Breast Cancer Information Core as an unclassified variant and lies in a conserved region of the gene in human, rat, and mouse; however, expression analysis would be required to elucidate the nature of this type of alteration.

The data presented here imply that germ-line mutations in the BRCA2 gene are involved in the development of one-third of male breast cancer cases in Hungary. There may be other genetic factors that are responsible for some of the male breast cancers that cannot be explained by mutations in the BRCA2 gene. There is no evidence for a male breast cancer-specific cluster region in the BRCA2 gene thus far, but because the majority of BRCA2 mutations found in male breast cancer are unique and not identified in female breast cancer cases, it is possible that at least some BRCA2 mutations may predispose to male rather than female breast cancer. On the other hand, certain mutations (e.g., 9326insA) result in both male and female breast cancers and can be associated with various phenotypes in different families. This could be explained by modifying factors in disease development different in males and females. The first evidence of a modifying genetic factor of BRCA2 in male breast cancer was provided recently (27) , reporting that an interstitial tandem duplication on 9p increases the risk of breast cancer in male patients conferred by BRCA2. The lack of a positive family history in all carriers suggests that at least some BRCA2 mutations may have a lower penetrance than others, and selection of putative BRCA2 mutation carriers among male breast cancer patients cannot be based on the family background of the disease. Our data provide further evidence that in certain populations there is a high genetic component in the development of this disease, and in these populations all patients with male breast cancer, regardless of their family history, should be screened for BRCA2 mutations.


   ACKNOWLEDGMENTS
 
We thank Janos Papp and Marco van der Looij for excellent technical help.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by Hungarian Research Grants OTKA (T19307) and OMFB (EU 96-D9-004; to E. O.) and a program grant from the Cancer Research Campaign (to B. P.). Back

2 To whom requests for reprints should be addressed, at Department of Molecular Biology, National Institute of Oncology, Rath Gyorgy Str. 7-9, H-1525 Budapest 114 Pf. 21, Hungary. Back

3 Breast Cancer in Men. http://interact.withus.com/interact/mbc/. Back

4 Unpublished data. Back

5 E. Olah et al., manuscript in preparation. Back

6 Breast Cancer Information Core. http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/. Back

Received 11/10/98. Accepted 1/15/99.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. La Vecchia C., Levi F., Lucchini F. Descriptive epidemiology of male breast cancer in Europe. Int. J. Cancer, 51: 62-66, 1992.[Medline]
  2. Szabo C. I., King M-C. Inherited breast and ovarian cancer. Hum. Mol. Genet., 4: 1811-1817, 1995.[Abstract]
  3. Ford D., Easton D. F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D. T., Weber B., Lenoir G., Chang-Claude J., Sobol H., Teare M. D., Stuewing J., Arason A., Scherneck S., Peto J., Rebbeck T. R., Tonin P., Neuhausen S., Barkardottir R., Eyfjord J., Lynch H., Ponder B. A. J., Gayther S. A., Birch J. M., Lindblom A., Stoppa-Lyonnet D., Bignon Y., Borg A., Hamann U., Haites N., Scott R. J., Maugard C. M., Vasen H., Seitz S., Cannon-Albright L. A., Schofield A., Zelada-Hedman M., the Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am. J. Hum. Genet., 62: 676-689, 1998.[Medline]
  4. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G., Barfoot R., Hamoudi R., Patel S., Rice C., Biggs P., Hashim Y., Smith A., Connor F., Arason A., Gudmundsson J., Ficenec D., Kelsell D., Ford D., Tonin P., Bishop D. T., Spurr N. K., Ponder B. A. J., Eeles R., Peto J., Devilee P., Cornelisse C., Lynch H., Narod S., Lenoir G., Egilsson V., Barkardottir R. B., Easton D. F., Bentley D. R., Futreal P. A., Ashworth A., Stratton M. R. Identification of the breast cancer susceptibility gene BRCA2. Nature (Lond.), 378: 789-792, 1995.[Medline]
  5. Ramus S. J., Kote-Jarai Z., van der Looij M., Gayther S. A., Csokay B., Ponder B. A. J., Olah E. Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast and breast-ovarian cancer. Am. J. Hum. Genet., 60: 1242-1246, 1997.[Medline]
  6. Anelli A., Anelli T. M. F., Youngson B., Rosen P. P., Borgen P. I. Mutations of the p53 gene in male breast cancer. Cancer (Phila.), 75: 2233-2238, 1995.[Medline]
  7. Lobaccaro J. M., Lumbroso S., Belon C., Galtier-Dereure F., Bringer J., Lesimple T., Namer M., Cutuli B. F., Pujol H., Sultan C. Androgen receptor gene mutation in male breast cancer. Hum. Mol. Genet., 2: 1799-1802, 1993.[Abstract/Free Full Text]
  8. Struewing J. P., Brody L. C., Erdos M. R., Kase R. G., Giambarresi T. R., Smith S. A., Collins F. S., Tucker M. A. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am. J. Hum. Genet., 57: 1-7, 1995.[Medline]
  9. Hogervorst F. B. L., Cornelis R. S., Bout M., van Vliet M., Oosterwijk J. C., Olmer R., Bakker B., Klijn J. G. M., Vasen H. F. A., Meijers-Heijboer H., Menko F. H., Cornelisse C. J., den Dunnen J. T., Devilee P., van Ommen G-J. B. Rapid detection of BRCA1 mutations by the protein truncation test. Nat. Genet., 10: 208-212, 1995.[Medline]
  10. Serova O. M., Montagna M., Torchard D., Narod S., Tonin P., Sylla B., Lynch H. T., Feunteun J., Lenoir G. M. A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. Am. J. Hum. Genet., 58: 42-51, 1996.[Medline]
  11. Couch F. J., Farid L. M., DeShano M. L., Tavtigian S. V., Calzone K., Campeau L., Peng Y., Bogden B., Chen Q., Neuhausen S., Shattuck-Eidens D., Godwin A. K., Daly M., Radford D. M., Sedlacek S., Rommens J., Simard J., Garber J., Merajver S., Weber B. L. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat. Genet., 13: 123-125, 1996.[Medline]
  12. Phelan C. M., Lancaster J. M., Tonin P., Gumbs C., Cochran C., Carter R., Ghadirian P., Perret C., Moslehi R., Dion F., Faucher M-C., Dole K., Karimi S., Foulkes W., Lounis H., Warner E., Goss P., Anderson D., Larsson C., Narod S. A., Futreal P. A. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat. Genet., 13: 120-122, 1996.[Medline]
  13. Thorlacius S., Olafsdottir G., Tryggvadottir L., Neuhausen S., Jonasson J. G., Tavtigian S. V., Tulinius H., Ogmundsdottir H. M., Eyfjord J. E. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat. Genet., 13: 117-119, 1996.[Medline]
  14. Hoskins K. F., Stopfer J. E., Calzone K. A., Merajver S. D., Rebbeck T. R., Garber J. E., Weber B. L. Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. J. Am. Med. Assoc., 273: 577-585, 1995.[Abstract/Free Full Text]
  15. Meyskens F. L., Jr., Tormey D. C., Neifeld J. P. Male breast cancer: a review. Cancer Treat. Rev., 3: 83-93, 1976.[Medline]
  16. Cutuli B., Dilhuydy J. M., De Lafontan B., Berlie J., Lacroze M., Lesaunier F., Graic Y., Tortochaux J., Resbeut M., Lesimple T., Gamelin E., Campana F., Reme-Saumon M., Moncho-Bernier V., Cuilliere J. C., Marchal C., De Gislain G., N'Guyen T. D., Teissier E., Velten M. Ductal carcinoma in situ of the male breast. Analysis of 31 cases. Eur. J. Cancer, 33: 35-38, 1997.
  17. Ramus S. J., Friedman L. S., Gayther S. A., Ponder B. A. J., Bobrow L., van der Looij M., Papp J., Olah E. A breast/ovarian cancer patient with germline mutations in both the BRCA1 and BRCA2 genes. Nat. Genet., 15: 14-15, 1997.[Medline]
  18. Tavtigian S. V., Simard J., Rommens J., Couch F., Shattuck-Eidens D., Neuhausen S., Merajver S., Thorlacius S., Offit K., Stoppa-Lyonnet D., Belanger C., Bell R., Berry S., Bogden R., Chen Q., Davis T., Dumont M., Frye C., Hattier T., Jammulapati S., Janecki T., Jiang P., Kehrer R., Leblanc J-F., Mitchell J. T., McArthur-Morrison J., Nguyen K., Peng Y., Samson C., Schroeder M., Snyder S. C., Steele L., Stringfellow M., Stroup C., Swedlund B., Swensen J., Teng D., Thomas A., Tran T., Tran T., Tranchant M., Weaver-Feldhaus J., Wong A. K. C., Shizuya H., Eyfjord J. E., Cannon-Albright L., Labrie F., Skolnick M. H., Weber B., Kamb A., Goldgar D. E. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat. Genet., 12: 333-337, 1996.[Medline]
  19. Serova O. M., Boutrand L., Stoppa-Lyonnet D., Bressac-de-Paillerets B., Dubois V., Lasset C., Janin N., Bignon Y., Longy M., Maugard C., Lidereau R., Leroux D., Frebourg T., Mazoyer S., Lenoir G. M. BRCA2 mutations in hereditary breast and ovarian cancer in France. Am. J. Hum. Genet., 60: 1236-1239, 1997.[Medline]
  20. Mavraki E., Gray I. C., Bishop D. T., Spurr N. K. Germline BRCA2 mutations in men with breast cancer. Br. J. Cancer, 76: 1428-1431, 1997.[Medline]
  21. Friedman L. S., Gayther S. A., Kurosaki T., Gordon D., Noble B., Casey G., Ponder B. A. J., Anton-Culver H. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am. J. Hum. Genet., 60: 313-319, 1997.[Medline]
  22. Haraldsson K., Loman N., Zhang Q-X., Johannsson O., Olsson H., Borg A. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res., 58: 1367-1371, 1998.[Abstract/Free Full Text]
  23. Thorlacius S., Sigurdsson S., Bjarnadottir H., Olafsdottir G., Jonasson J. G., Tryggvadottir L., Tulinius H., Eyfjord J. E. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am. J. Hum. Genet., 60: 1079-1084, 1997.[Medline]
  24. Rosenblatt K. A., Thomas D. B., McTiernan A., Austin M. A., Stalsberg H., Stemhagen A., Thompson W. D., Curnen M. G., Satariano W., Austin D. F. Breast cancer in men: aspects of familial aggregation. J. Natl. Cancer Inst., 83: 849-854, 1991.[Abstract/Free Full Text]
  25. Donegan W. L., Redlich P. N. Breast cancer in men. Surg. Clin. N. Am., 76: 343-363, 1996.
  26. Neuhausen S. L., Godwin A. K., Gershoni-Baruch R., Schubert E., Garber J., Stoppa-Lyonnet D., Olah E., Csokay B., Serova O., Lalloo F., Osorio A., Stratton M., Offit K., Boyd J., Caligo M. A., Scott R. J., Schofield A., Teugels E., Schwab M., Cannon-Albright L., Bishop T., Easton D., Benitez J., King M-C., Ponder B. A. J., Weber B., Devilee P., Borg A., Narod S. A., Goldgar D. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am. J. Hum. Genet., 62: 1381-1388, 1998.[Medline]
  27. Savelyeva L., Claas A., Gier S., Schlag P., Finke L., Mangion J., Stratton M. R., Schwab M. An interstitial tandem duplication of 9p23–24 coexist with a mutation in the BRCA2 gene in the germ line of three brothers with breast cancer. Cancer Res., 58: 863-866, 1998.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
Y. C. Tai, S. Domchek, G. Parmigiani, and S. Chen
Breast Cancer Risk Among Male BRCA1 and BRCA2 Mutation Carriers
J Natl Cancer Inst, December 5, 2007; 99(23): 1811 - 1814.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. R. Weiss, K. B. Moysich, and H. Swede
Epidemiology of Male Breast Cancer
Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 20 - 26.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Liede, B. Y. Karlan, and S. A. Narod
Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature
J. Clin. Oncol., February 15, 2004; 22(4): 735 - 742.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Kwiatkowska, M. Teresiak, V. Filas, A. Karczewska, D. Breborowicz, and A. Mackiewicz
BRCA2 Mutations and Androgen Receptor Expression as Independent Predictors of Outcome of Male Breast Cancer Patients
Clin. Cancer Res., October 1, 2003; 9(12): 4452 - 4459.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Ottini, G. Masala, C. D'Amico, B. Mancini, C. Saieva, G. Aceto, D. Gestri, V. Vezzosi, M. Falchetti, M. De Marco, et al.
BRCA1 and BRCA2 Mutation Status and Tumor Characteristics in Male Breast Cancer: A Population-based Study in Italy
Cancer Res., January 15, 2003; 63(2): 342 - 347.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
S. H. Giordano, A. U. Buzdar, and G. N. Hortobagyi
Breast Cancer in Men
Ann Intern Med, October 15, 2002; 137(8): 678 - 687.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
E Kwiatkowska, I Brozek, E Izycka-Swieszewska, J Limon, and A Mackiewicz
Novel BRCA2 mutation in a Polish family with hamartoma and two male breast cancers
J. Med. Genet., July 1, 2002; 39(7): e35 - 35.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
D. Thompson and D. Easton
Variation in BRCA1 Cancer Risks by Mutation Position
Cancer Epidemiol. Biomarkers Prev., April 1, 2002; 11(4): 329 - 336.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. S. Sinclair, R. Berry, D. Schaid, S. N. Thibodeau, and F. J. Couch
BRCA1 and BRCA2 Have a Limited Role in Familial Prostate Cancer
Cancer Res., March 1, 2000; 60(5): 1371 - 1375.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Csokay, B.
Right arrow Articles by Olah, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Csokay, B.
Right arrow Articles by Olah, E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online